โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

Study Of ATRN-119 In Patients With Advanced Solid Tumors

(ABOYA-119)

Sponsored by Aprea Therapeutics

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Active, Not Recruiting

Auto-verified from ClinicalTrials.gov

Verified Jan 26, 2026

Phase

Clinical Trial

Sponsor

Aprea Therapeutics

Enrollment Target

132

Start Date

Jan 2023

๐Ÿ“Š
1 of 132 participants interested
1% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.

Who Can Participate

Inclusion Criteria

DNA damage response (DDR) mutations documented in the past medical record or confirmed during the screening period.
Measurable disease defined by RECIST 1.1.
Life expectancy โ‰ฅ 3 months.
Subject must be capable of oral administration of study medication.

Exclusion Criteria

Patient has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks.
Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119.
Concomitant treatment with strong inhibitors or inducers of CYP3A4 and CYP2D6.
Known human immunodeficiency virus infection (HIV).
Subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications.
Current or past diagnosis of leukemia within the past 5 years.
Prior radiotherapy at the target lesion unless there is evidence of disease progression.
Known CNS metastases or clinical evidence of CNS involvement that is not stable

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

132 participants

โšง

Gender

ALL

๐Ÿข

Sponsor

Aprea Therapeutics

Study Locations

Choose your preferred location or select flexible during enrollment

Unknown

New Haven

Connecticut

Location available
View New Haven location page
Unknown

Cleveland

Ohio

Location available
View Cleveland location page
Unknown

Philadelphia

Pennsylvania

Location available
View Philadelphia location page
Unknown

Dallas

Texas

Location available
View Dallas location page
Unknown

Irving

Texas

Location available
View Irving location page
Unknown

San Antonio

Texas

Location available
View San Antonio location page
Unknown

Fairfax

Virginia

Location available
View Fairfax location page

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Advanced Solid Tumors Trials by City

Browse all advanced solid tumors clinical trials in these cities โ€” not just this study.

Looking for Advanced Solid Tumor Treatment in New Haven?

Join others in Connecticut exploring innovative treatment options through clinical research

Advanced Solid Tumor Treatment Options in New Haven, Connecticut

If you're searching for Advanced Solid Tumor treatment in New Haven, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in New Haven, Cleveland, Philadelphia and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Advanced Solid Tumor. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Connecticut
Now Enrolling
Up to 132 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Advanced Solid Tumor?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Advanced Solid Tumor

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Advanced Solid Tumor Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT04905914. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.